Immunohistochemical analysis of estramustine binding protein with particular reference to proliferative activity in human prostatic carcinoma

Shiina, Hìroaki; Igawa, Mikio; Shigeno, Kazushi; Wada, Yakihiro; Yoneda, Tatsuaki; Shirakawa, Hiroki; Ishibe, Tomoyuki; Shirakawa, Ritsuko; Nagasaki, Makoto; Shirane, Takeshi; Usui, Tsuguru

doi:10.1002/(sici)1097-0045(19970615)32:1<49::aid-pros7>3.0.co;2-7

Cited by 6 publications

(3 citation statements)

References 33 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Several immunochemical studies have indicated that the tumor cell expression of prostatein/EMBP can provide useful prognostic information and perhaps predict responsiveness to estramustine (Estracyt) treatment in patients with prostate cancer [15–18]and other malignancies [19, 20]. The precise structural characterization of these human lipophilins will facilitate studies to examine their effects on the responses of normal and malignant cells to steroids.…”

Section: Discussionmentioning

confidence: 99%

Lipophilin, a novel heterodimeric protein of human tears

Lehrer

Abduragimov

et al. 1998

FEBS Letters

View full text Add to dashboard Cite

We identified a novel heterodimeric protein, lipophilin AC, in human tears. One of its components, lipophilin A (69 residues; mass, 7575.1; pI, 9.47) was homologous to the C1 and C2 components of prostatein (`estramustine-binding protein'), the major secreted protein of rat prostate. Human lipophilin C (77 residues; mass, 8854.1; pI, 4.94) was homologous to the rat prostatein C3 component and to human mammaglobin, a protein overexpressed in some mammary carcinomas. Tear lipophilins A and C expand the roster of human uteroglobin superfamily members and provide models for exploring these typically steroid-regulated and steroid-binding molecules.z 1998 Federation of European Biochemical Societies.

show abstract

Section: Discussionmentioning

confidence: 99%

Lipophilin, a novel heterodimeric protein of human tears

Lehrer

Abduragimov

et al. 1998

FEBS Letters

View full text Add to dashboard Cite

show abstract

“…It is located on chromosome 17q21 and codes for an 18.5-kDa protein containing 166 amino acids which functions as nucleoside diphosphate kinase and protein-histidine kinase [189,190]. Clinically, NM23 has been shown to be down-regulated in a variety of tumors including breast and prostate cancers [191,192]. Ectopic expression of NM23 has also been shown to significantly reduce the in vitro and in vivo metastatic potential of highly metastatic carcinoma cell lines including breast, melanoma, colon, and oral squamous cells [190,[193][194][195].…”

Section: Nm23mentioning

confidence: 99%

Solidago Virgaurea for Prostate Cancer Therapy

Watabe¹

2010

View full text Add to dashboard Cite

Public reporting burden for this collection of information is estimated to average 1 hour per response, including the time for reviewing instructions, searching existing data sources, gathering and maintaining the data needed, and completing and reviewing this collection of information. Send comments regarding this burden estimate or any other aspect of this collection of information, including suggestions for reducing this burden to Department of Defense, Washington Headquarters Services, Directorate for Information Operations and Reports (0704-0188), 1215 Jefferson Davis Highway, Suite 1204, Arlington, VA 22202-4302. Respondents should be aware that notwithstanding any other provision of law, no person shall be subject to any penalty for failing to comply with a collection of information if it does not display a currently valid OMB control number. PLEASE DO NOT RETURN YOUR FORM TO THE ABOVE ADDRESS.

show abstract

Section: Metastasis Suppressorsmentioning

confidence: 99%

Drug development against metastasis-related genes and their pathways: A rationale for cancer therapy

Iiizumi

Pai

et al. 2008

Biochimica et Biophysica Acta (BBA) - Reviews on Cancer

View full text Add to dashboard Cite

It is well recognized that the majority of cancer related deaths is caused by metastatic disease. Therefore, there is an urgent need for the development of therapeutic intervention specifically targeted to the metastatic process. In the last decade, significant progress has been made in this research field, and many new concepts have emerged that shed light on the molecular mechanism of metastasis cascade which is often portrayed as a succession of six distinct steps; localized invasion, intravasation, translocation, extravasation, micrometastasis and colonization. Successful metastasis is dependent on the balance and complex interplay of both the metastasis promoters and suppressors in each step. Therefore, the basic strategy of our interventions is aimed at either blocking the promoters or potentiating the suppressors in this disease process. Toward this goal, various kinds of antibodies and small molecules have been designed. These include agents that block the ligandrecepter interaction of metastasis promoters (HGF/c-Met), antagonize the metastasis promoting enzymes (AMF,uPA and MMP) and inhibit the transcriptional activity of metastasis promoter (β-Catenin). On the other hand, the intriguing roles of metastasis suppressors and their signal pathways have been extensively studied and various attempts have been made to potentiate these factors. Small molecules have been developed to restore the expression or mimic the function of metastasis suppressor genes such as NM23, E-cadherin, Kiss-1, MKK4 and NDRG1, and some of them are under clinical trials. This review summarizes our current understanding of the molecular pathway of tumor metastasis and discusses strategies and recent development of anti-metastatic drugs.

show abstract

Immunohistochemical analysis of estramustine binding protein with particular reference to proliferative activity in human prostatic carcinoma

Cited by 6 publications

References 33 publications

Lipophilin, a novel heterodimeric protein of human tears

Lipophilin, a novel heterodimeric protein of human tears

Solidago Virgaurea for Prostate Cancer Therapy

Drug development against metastasis-related genes and their pathways: A rationale for cancer therapy

Contact Info

Product

Resources

About